50% off Premium Yearly

TSE:MDA
Last week, the Telesat deal surprised everyone. Nobody saw it coming. MDA developed a technology that really dropped the costs, so they were able to raise the financing. That deal was a feather in the cap, but MDA's demand will grow anyway. He likes the story and is hanging on, not selling any shares.
EPS of 8c mostly matched estimates (8.2c); revenue of $196M was 1% better than expected. EBITDA of $40.4M was 11.5% better. Results were good, and guidance was raised. MDA also won a very large contract which adds significantly to earnings/revenue visibility. The stock has had a very big run; at 28X earnings it cannot be called cheap, but we think momentum can continue. We can't comment on position size but think it is buyable for aggressive investors, though we would not expect the same pace as recent gains.
Unlock Premium - Try 5i Free
He's been buying this all along. It bottomed at $6 and is now around $8.50. They're like the arms dealer in the old space race--making components in satellites. They're very well positioned. Are generating cash flow and raised full-year guidance. Delivered a good beat last quarter. Their valuation will expand. Satellites will continue to launch so there will be demand.
MDA Ltd. is a Canadian stock, trading under the symbol MDA.TO (previously MDA-T on Stockchase) on the Toronto Stock Exchange (MDA-CT). It is usually referred to as TSX:MDA or MDA.TO
In the last year, no analyst issued a Buy, Sell, or Hold rating on MDA.TO (previously MDA-T on Stockchase) on Stockchase. Read the latest expert commentary for MDA Ltd..
MDA Ltd. was recommended as a Top Pick by John Zechner on 2021-10-04. Read the latest stock experts ratings for MDA Ltd..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for MDA Ltd..
MDA Ltd. is followed by 27 investors on Stockchase and is a trending stock that is worth watching.
On 2026-06-19, MDA Ltd. (MDA.TO) stock closed at a price of $59.11.
Forecasts call for sales growth of 23.5% and EPS growth of 21.1% in 2024. MDA has displayed nice momentum following a solid Q3 and has a large backlog of business. Additionally, MDA has started to see cash flows begin to increase. MDA is up 59% in the last year and a valuation of 17.9x forward earnings is decent considering the strong momentum in the last year and forecasted outlook. We are comfortable adding to MDA at the current levels.
Unlock Premium - Try 5i Free